Share This Page
Drug Price Trends for FARESTON
✉ Email this page to a colleague
Best Wholesale Price for FARESTON
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Unit | Dates | Price Type |
|---|---|---|---|---|---|---|---|---|
| FARESTON 60MG TAB | Kyowa Kirin, Inc. | 42747-0327-30 | 30 | 1306.48 | 43.54933 | EACH | 2024-01-01 - 2027-09-29 | FSS |
| FARESTON 60MG TAB | Kyowa Kirin, Inc. | 42747-0327-30 | 30 | 587.92 | 19.59733 | EACH | 2022-09-30 - 2027-09-29 | FSS |
| FARESTON 60MG TAB | Kyowa Kirin, Inc. | 42747-0327-30 | 30 | 636.13 | 21.20433 | EACH | 2023-01-01 - 2027-09-29 | FSS |
| FARESTON 60MG TAB | Kyowa Kirin, Inc. | 42747-0327-30 | 30 | 877.09 | 29.23633 | EACH | 2024-01-01 - 2027-09-27 | Big4 |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Unit | >Dates | >Price Type |
Market Analysis and Price Projections for FARESTON (Toremifene Citrate)
Introduction
FARESTON (toremifene citrate) stands as a widely prescribed selective estrogen receptor modulator (SERM) approved primarily for treating metastatic breast cancer in postmenopausal women. Since its initial approval by the U.S. Food and Drug Administration (FDA) in 1989, FARESTON has maintained a pivotal role within oncology treatment protocols, particularly for hormone-receptor-positive breast cancer. This analysis evaluates its current market dynamics, competitive landscape, and offers price projections considering evolving factors in the pharmaceutical industry.
Current Market Landscape
Therapeutic Position and Market Demand
FARESTON’s positioning as an orphan drug for metastatic breast cancer confers both advantages and limitations. Due to its specific indication, the global patient population remains relatively niche; however, the prevalence of breast cancer — estimated at 2.3 million new cases annually worldwide and approximately 250,000 in the U.S. alone — sustains steady demand for targeted hormonal therapies.
In clinical practice, FARESTON has largely been supplanted by aromatase inhibitors and newer SERMs, such as tamoxifen and others, especially in earlier disease stages. Nonetheless, FARESTON continues to serve as a second-line agent or alternative in specific cohorts where resistance or tolerability issues arise.
Market Size and Revenue Projections
According to industry reports, the global breast cancer drug market was valued at approximately USD 18 billion in 2021, with targeted hormonal agents accounting for roughly 40%. Within this subset, the market for SERMs like FARESTON is estimated at USD 600-800 million, considering its niche application.
The U.S. market contributes about 50% of this revenue, with pharmacoeconomic scrutiny, patent expirations, and emerging therapies influencing future sales.
Competitive Landscape
FARESTON faces competition primarily from tamoxifen, aromatase inhibitors (e.g., anastrozole, letrozole), and newer targeted agents including CDK4/6 inhibitors (e.g., palbociclib). These alternatives often offer improved efficacy or better tolerability profiles. Consequently, FARESTON's market share has declined among frontline therapies, but persists in specific treatment sequences and patient subsets.
Key competitors' patent protections and formulation developments influence market accessibility. For instance, generic versions of toremifene citrate are available, increasing price sensitivity and market penetration in low- and middle-income regions.
Regulatory and Reimbursement Factors
Regulatory agencies in major markets are increasingly emphasizing personalized medicine and biomarker-driven treatment. Although FARESTON remains FDA-approved for its original indication, off-label uses and its potential in combination therapies are under evaluation, which could expand or constrict its market.
Reimbursement policies, especially in the U.S. Medicare and private payer systems, tend to favor cost-effective agents. The availability of generics significantly impacts pricing strategies, often leading to substantial price erosion over time.
Pricing Trends and Projections
Historical Pricing Dynamics
Historically, FARESTON’s branded formulation has maintained a premium over generic alternatives. As of 2022, the average wholesale price (AWP) for a 20 mg to 60 mg daily dose ranged from USD 600 to USD 800 per month per patient, with variations based on geographic location, healthcare setting, and payer negotiations.
Patent expirations in the mid-2010s prompted a steep decline in prices, with generic toremifene citrate now dominating the market, reducing costs by approximately 50% or more. This trend reflects standard lifecycle progression for branded oncology drugs.
Factors Influencing Future Price Trajectories
- Generic Competition: Increasing prevalence of generics favors downward pricing pressures. The number of generics entering the market correlates strongly with price erosion.
- Market Penetration and Adoption: As clinical guidelines evolve, if FARESTON finds renewed utility—such as in combination therapies or extended indications—its demand and price could stabilize or slightly increase.
- Regulatory Changes: Potential regulatory barriers or incentives for biosimilars or next-generation SERMs may influence the pricing landscape.
- Emerging Therapies: The success of novel agents in overcoming resistance to existing hormonal therapies could diminish FARESTON's market share, further compressing prices.
Forecasted Price Range (Next 5-10 Years)
Based on current trends and industry modeling:
- Best-Case Scenario: If FARESTON maintains niche therapeutic relevance, with minimal additional patent protections, prices could stabilize around USD 300–USD 500 per month per patient, factoring in inflation and payer negotiations.
- Moderate Decline Scenario: A surge in generic penetration might reduce prices by 60–70%, pushing costs below USD 300 per month.
- Worst-Case Scenario: In the event of obsolescence due to superior therapies, FARESTON’s price could approach marginal costs, potentially below USD 200 per month, or data exclusivity might be extended through orphan drug protections, temporarily stabilizing prices.
Implications for Stakeholders
- Pharmaceutical Manufacturers: Opportunities exist to capitalize on market niches or develop combination formulations or biosimilars to sustain revenue streams.
- Healthcare Providers and Payers: Cost considerations and emerging therapies necessitate strategic formulary management.
- Patients: Access affordability remains sensitive to drug pricing, especially as generics dominate.
Conclusion
FARESTON’s market is characterized by steady demand within a niche, declining premium pricing due to generic competition, and evolving therapeutic landscapes that threaten its future market share. Strategic positioning, potential label expansions, and biosimilar development could influence future prices, but conservative estimates suggest gradual price declines over the next decade.
Key Takeaways
- FARESTON's global market remains modest but is supported by its specific postmenopausal breast cancer indication.
- The entry of generics significantly reduced prices, with current estimates hovering between USD 300–USD 500 per month.
- Shifts toward newer therapies and biomarkers may further erode FARESTON’s market share, pressuring prices downward.
- Opportunities for differentiation include combination therapies or niche indications, potentially stabilizing prices temporarily.
- Stakeholders should monitor regulatory developments, clinical guideline updates, and patent landscapes to optimize positioning.
FAQs
-
What is the primary indication for FARESTON?
FARESTON is approved for treating metastatic, hormone-receptor-positive breast cancer in postmenopausal women. -
How does FARESTON’s market share compare to other SERMs?
While historically significant, FARESTON’s market share has declined due to competition from tamoxifen, aromatase inhibitors, and newer targeted agents. -
What are the key factors affecting FARESTON’s future price?
Generic competition, clinical utility, regulatory changes, and emerging therapies influence its price trajectory. -
Are there upcoming developments that could impact FARESTON’s market?
Potential label expansions, new combination regimens, or biosimilar entries could either boost or diminish its market presence. -
How accessible is FARESTON globally considering current pricing trends?
Generic availability has improved affordability in many regions, but access remains dependent on healthcare infrastructure and reimbursement policies.
Sources:
[1] Global Data, "Breast Cancer Market Analysis," 2022.
[2] U.S. FDA, "Approval History of FARESTON," 1989–2022.
[3] IQVIA, “Pharmaceutical Pricing and Market Trends,” 2022.
[4] World Health Organization, "Cancer Statistics," 2022.
[5] EvaluatePharma, "Oncology Drug Market Forecasts," 2022.
More… ↓
